On 18 November 2016, orphan designation (EU/3/16/1770) was granted by the European Commission to Minoryx Therapeutics S.L., Spain, for 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride (also known as MIN-102) for the treatment of adrenoleukodystrophy.
|Disease / condition||
Treatment of adrenoleukodystrophy
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.